Rapid Investments is a non-banking financial company (NBFC) that provides secured loans, financial advisory services, and investment management primarily to retail and corporate clients in India.
The company operates as a commodity lender with no identifiable competitive advantage, evidenced by a low average ROCE of 3.6% and a negative cash conversion cycle. The business lacks scale, brand power, or proprietary technology to differentiate its lending products from larger, more efficient competitors.
Management has focused on reviving a previously revoked NBFC license and recently executed a rights issue to bolster a small capital base. However, historical returns on equity are poor, and significant funds are tied up in related-party loan portfolios rather than high-yield organic growth.
The company's collapse was driven by the realization that the loan book was largely a circular financing scheme for related parties rather than a productive credit engine. As the RBI tightened oversight on NBFC governance, the historical license revocations and lack of internal controls became terminal liabilities. The negative cash conversion cycle eventually starved the firm of liquidity, and without a genuine competitive advantage or scale, the business was unable to outrun its poor capital allocation decisions, leading to a permanent impairment of shareholder equity.
RichFakir rates Rapid Investments Ltd's business quality as poor — 26/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Rapid Investments Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Rapid Investments Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Rapid Investments Ltd's fair value is about ₹14 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →